Kornimate/medical-research-clean huggingface dataset:
digital cbt-i for insomnia disorder

Conditions: Insomnia Disorder

Summary: this study will examine the effectiveness of digital cbt-i versus sleep hygiene education in reducing insomnia severity, sleep onset latency, and wake after sleep onset in those with insomnia disorder.

this study aims to examine the effectiveness of a fully-automated web and app-based digital cbt-i for insomnia compared to sleep hygiene education (she) in individuals with a diagnosis of insomnia disorder. primary outcomes of interest include changes in insomnia severity, sleep onset latency, and wake after sleep onset throughout the course of the study.

Eligibility criteria:
inclusion criteria: * age ≥22 years old * insomnia disorder diagnosis * score ≤16 on the 8-item sleep condition indicator * \> 30 minutes sleep onset latency (sol); and/or \> 30 minutes wake after sleep onset (waso) * current resident of the usa * oral and written fluency in english * participant is able and willing to comply with protocol requirements, has been informed of the nature of the study, and has signed the irb-approved informed consent form exclusion criteria: * must not be currently receiving or be expecting to start cbt for insomnia during study participation, or have previously received cbt for insomnia in the past 12-months (self-report) * if on psychoactive medication, including sleep medication, this must be stable for at least 5 half lives * past or present psychosis, schizophrenia, bipolar disorder, assessed by self-report and/or seizure disorder * occupation that requires alertness / caution to avoid accidents, for example long-haul driving, long distance bus driver, heavy machinery operator, air traffic controller * hearing or vision impairment that prevents effective use of the audio-visual content of digital cbt-i or she in the opinion of the investigator * intellectual disability or any neurocognitive or neurodevelopmental disorder that would prevent participants from following study procedures * any condition that the investigator believes would make participation in the study not in the best interest of the participant or would preclude successful completion of study activities

Keywords: insomnia digital cbt cbt-i
correlating the measure of retinal vascular density through angio-oct with calcium score

Conditions: Cardiovascular Abnormalities; Vascular Diseases; Retinal Vascular

Summary: recent case-control studies have proven that the retinal vascularization mirrors the cardiac vascularization: more the coronary network is altered, more the density of retinal vessels is reduced. no studies have yet been realised in primary prevention. this study aims to demonstrate a link between the density of the retinal vascularization and the calcium score, which is currently the gold standard for the classification of cardiovascular risk in primary prevention. thus, a simple image of the retinal vascularization could predict the cardiovascular risk of a patient. oct angiography would become a major aid in the classification of cardiovascular risk in asymptomatic patients.


Eligibility criteria:
inclusion criteria: * patients eligible for a calcium score as part of their standard treatment and volunteers for an ophthalmologic consultation exclusion criteria: * pregnant women
injection of ex vivo amplified g-csf mobilised autologous peripheral blood stem cell transplantation

Conditions: Multiple Myeloma

Summary: hematopoietic reconstitution defined by a neutrophils number \> 500/mm3 at day 7 after injection of ex vivo amplified graft and by a platelets number \> 20000/mm3, at day 15 after the injection of ex vivo amplified graft, without transfusion.

to check that injection of autologous peripheral blood stem cell cd34(+) "amplified ex vivo in the presence of scf, g-csf and tpo in hp01 maco pharma medium culture. ": allows to obtain a hematopoietic reconstitution: 1. rapid : 7 days or less after the injection, regarding neutrophils and 15 days or less regarding platelets 2. complete: numbers neutrophils and platelets respectively higher than 500/mm3 and 20000/mm3 within the times mentioned 3. stable: no secondary neutropenia or thrombocytopenia during the year following the injection, in the absence of recurence of the myeloma.

Eligibility criteria:
inclusion criteria: * patient between 18 and 65 years of age * diagnosis of multiple myeloma, requiring a treatment, including high dose melphalan whith autologous peripheral blood stem cell transplantation * performance status: \ 70%) * anticipated survival \> 3 month * collection of a minimum of 10x106 cells (cd34+)/kg of autologous g-csf mobilised peripheral blood stem cells in 2 to 3 pheresis. * signed and dated informed consent exclusion criteria: * multiple myeloma not requiring a treatment * another cancer in the 5 years preceding the diagnosis or evolutive psychiatric affection * positive serology for hiv, hepatitis c or hepatitis b * hepato cellular insufficiency * severe renal insufficiency defined by a creatine clearance \< 30 ml/mn * women pregnant or nursing, or effective absence of contraception * antecedent of serious cardiac disease in the last 6 months. * allergy known to the products derived from escherichia coli

Keywords: symptomatic multiple myeloma first line treatment first autologous stem cell transplantation ex vivo amplified autologous peripheral blood stem cells
low temperature plasma ablation combined lacrimal duct catheterization in the treatment of lacrimal duct obstructive

Conditions: Lacrimal Duct Obstruction

Summary: to compare the clinical effects of low temperature plasma ablation combined with lacrimal duct catheterization and yag lacrimal duct laser combined with lacrimal duct catheterization in the treatment of lacrimal duct obstruction

low-temperature plasma technology has developed rapidly in recent decades and is now widely used in ophthalmology, otolaryngology, orthopedics, urology and other fields .the low-temperature plasma surgery system relies on a 100khz radio frequency electric field to excite normal saline (0.9% nacl) to generate plasma energy, and relies on a 50-100 μm plasma layer generated at the front of the plasma knife to perform precise cutting, ablation and hemostaxy. but the application of this technique in the field of lacrimal duct still needs the accumulation of clinical experience.this study was aimed to compare the clinical effects of low temperature plasma ablation combined with lacrimal duct catheterization and yag lacrimal duct laser combined with lacrimal duct catheterization in the treatment of lacrimal duct obstruction

Eligibility criteria:
inclusion criteria: * ① sign the informed consent for this study voluntarily * ≥18 years old and \< 70 years old (3) single lacrimal tract obstruction was included in the study * no purulent secretion of lacrimal passage exclusion criteria: * patients who meet any of the following criteria will not be eligible for inclusion in this study: * have a history of lacrimal duct surgery, including lacrimal duct catheterization, laser lacrimal duct plasty, etc * have a history of allergy to hormones and antibiotics * congenital lacrimal duct malformation * nasal trauma and deformation ⑤ patients with severe abnormal liver and kidney function and cardiovascular and cerebrovascular diseases in addition to lacrimal duct obstruction, there are other ophthalmic diseases ⑦ exclude diabetes * exclusion of pregnancy, lactation women ⑨ not willing to participate in research

Keywords: lacrimal duct obstruction low temperature plasma ablation
relative bronchodilating effects of formoterol when administered via symbicort pressurized metered-dose inhaler (pmdi) or oxis turbuhaler

Conditions: Stable Asthma

Summary: the purpose of this study is to compare the therapeutic effects of formoterol in symbicort with formoterol in oxis turbuhaler for the treatment of adults with stable asthma.


Eligibility criteria:
inclusion criteria: * at least 18 years of age * diagnosis of asthma and baseline lung function tests as determined by the protocol * required and received treatment with inhaled corticosteroids within timeframe and doses specified in the protocol exclusion criteria: * severe asthma * has required treatment with any non-inhaled corticosteroids within previous 4 weeks, has sensitivity to drugs specified in protocol or requires treatment with beta-blockers

Keywords: stable asthma adults formoterol symbicort oxis turbuhaler bronchodilation
timely detection of treatment emergent serious and non-serious adverse events for saxenda® in mexican patients

Conditions: Obesity

Summary: this trial is conducted in north america. the aim is to investigate timely detection of pancreatitis cases as well as cases of suspicion of serious and non-serious adverse reactions possibly or probably related to saxenda® in mexican patients.


Eligibility criteria:
inclusion criteria: * signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol) * the decision to initiate the treatment with commercially available saxenda® has been made by the patient/legally acceptable representative (lar) and the treating physician before and independently from the decision to include the patient in this study * obese patients (bmi equal to or above 30 kg/m\^2) or overweight patients (bmi equal to or above 27 kg/m\^2) with at least one weight related comorbidity according to saxenda® label text in mexico * age equal or above 18 years at the time of signing informed consent exclusion criteria: * mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation * hypersensitivity to saxenda® or to any of its excipients * females of child-bearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practice) * diagnosis of type 1 diabetes
prebiotic fructans on the incidence of acute infectious diseases in children

Conditions: Infectious Disease; Children, Only; Diet Modification

Summary: the study aims to explore whether prophylactic dietary supplementation with prebiotic inulin-type fructans is able to influence the intestinal microbiota and the frequency of infectious disease episodes in kindergarten children during a winter period.


Eligibility criteria:
inclusion criteria: * subject is healthy at the time of pre-examination * subject is aged 3-6 years at the time of pre-examination * subject attends a kindergarten at the time of pre-examination exclusion criteria: * congenital disease or malformation influencing the gastrointestinal system * children with congenital or acquired immunodeficiency * children with food intolerance, food allergy or metabolic disorder requiring special diet * children who regularly (more than 3 times per week) consumed products or food supplements containing prebiotics or probiotics * children who consumed antibiotics or laxatives within 14 days * children who had any infectious disease within 14 days at the time of pre-examination
safety and efficacy of idec-114 in combination with rituxan in the treatment of non-hodgkin's lymphoma

Conditions: Non-Hodgkin's Lymphoma

Summary: to determine what side effects and what clinical effect, if any, the administration of this investigational product, idec-114 in combination with rituxan® \[rituxan® as a single agent is approved by the united states food and drug administration (fda) to treat patients with relapsed or refractory follicular nhl\], has in this patient population.


Eligibility criteria:
inclusion criteria: * signed irb-approved informed consent * greater than or equal to 18 years of age * proof of follicular lymphoma * progressive disease requiring treatment after at least 1 prior standard therapy * acceptable hematologic status, liver function, and renal function * patients of reproductive potential must agree to follow accepted birth control methods during treatment and for 3 months after completion of treatment exclusion criteria: * no response to prior rituxan® or rituxan®-containing regimen * presence of cll or cns lymphoma * known history of hiv infection or aids * prior diagnosis of aggressive nhl or mantle-cell lymphoma * serious nonmalignant disease * pregnant or currently breast feeding
study of teriparatide in stress fracture healing

Conditions: Stress Fracture; Parathyroid Hormone

Summary: investigation into the use of teriparatide in the treatment of stress fractures. primary outcome is healing on mri, secondary outcomes are pain, time spent in rehabilitation and future stress fractures. this study will help the investigators understand how to treat stress fractures in the future.

teriparatide is a drug that is designed to have a similar effect on the body as parathyroid hormone. parathyroid hormone is made naturally in the body and is released in response to low calcium levels. it helps to maintain bone health and repair bone damage. parathyroid hormone and medicines like teriparatide can strengthen bones and are often given to people with osteoporosis (a condition that weakens bones, making them more likely to break) to reduce the risk of fractures. recent studies have also shown benefits in people with stress fracture injuries, a form of bone damage sometimes caused by repetitive exercise. the investigators want to know if teriparatide is also beneficial to healthy, younger people who have a stress fracture injury.

Eligibility criteria:
inclusion criteria: 1. signed informed consent form; 2. participant must be aged 18 - 40 years inclusive; 3. participant must have a lower limb stress fracture, either unilateral or bilateral, as confirmed via mri scan; 4. undergoing phase 1 or 2 training within an army training establishment; 5. blood tests within reference range. minor abnormalities will be assessed by the pi. patients will still be entered if these are felt to be of no clinical importance. 6. participants able to adhere to the visit schedule and protocol requirements. exclusion criteria: 1. hypersensitivity to the active parathyroid hormone substance or any of the excipients listed in the smpc. 2. pre-existing hypercalcaemia. 3. patients with skeletal malignancies or bone metastases. 4. any contraindications that would prevent the participant from undergoing an mri scan. 5. concurrent therapy that, in the investigators opinion, would interfere with the evaluation of the safety or efficacy of the study medication. 6. pregnancy, suspected pregnancy or breastfeeding. female participants must have a negative serum pregnancy test at screening and be willing and able to use a "highly effective" method of contraception, as per the clinical trial facilitation group (ctfg) guidance. 7. severe renal impairment. participants with moderate renal impairment will be treated with caution at the principal investigator's discretion and in accordance with the smpc. 8. metabolic bone diseases including hyperparathyroidism and paget's disease of the bone. 9. unexplained elevations of alkaline phosphatase. 10. prior external beam or implant radiation therapy to the skeleton. 11. patients participating in a concurrent drug trial. 12. presentation with open epiphyses during the diagnostic mri scan. 13. participants with depression, as identified by completion of the columbia-suicide severity rating scale (c-ssrs) at baseline.
carotid atherosclerosis and vascular events in people with diabetes

Conditions: Carotid Atherosclerosis

Summary: diabetes is a risk factor for carotid atherosclerotic whose progression is associated with an increased risk of vascular events. investigators assessed prospectively by arterial duplex ultrasonography the progression of carotid atherosclerosis in a cohort of people with diabetes to assess the importance of progression and to analyze the impact of this progression on vascular events. the main hypothesis is that people with carotid atherosclerosis progression are at higher risk of vascular events than those without any progression.


Eligibility criteria:
inclusion criteria: * age \>18 ans * diabetes * carotid duplex ultrasonography in 2012 exclusion criteria: * none

Keywords: carotid atherosclerosis duplex ultrasonography diabetes vascular events
hypofractionated proton radiation therapy for low and intermediate risk prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this trial is to give a shorter course (5 ½-6 weeks) of proton radiation that has as little side effects on normal bladder and rectal tissues as the usual longer course (8 weeks) of proton radiation, without decreasing the chance of killing prostate cancer cells.


Eligibility criteria:
inclusion criteria: * prostate cancer. * gleason score 2-6 or 7. * psa ≤ 20 ng/ml. exclusion criteria: * previous prostate cancer surgery or pelvic radiation. * prior/concurrent systemic chemotherapy for prostate cancer. * active inflammatory bowel disease (crohn's disease, diverticulitis or ulcerative colitis) affecting the rectum. * history of hip replacement. * prior intrapelvic surgery. * taking saw palmetto or methotrexate and unable or unwilling to discontinue its uses during radiation. * receiving continuous and current anticoagulation with warfarin sodium (coumadin), clopidogrel bisulfate (plavix), dabigatran etexilate mesylate (pradaxa),enoxaparin sodium (lovenox), or aspirin/er dipyridamole (aggrenox).

Keywords: proton radiation, prostate cancer
rehabilitation study in ms patients

Conditions: Multiple Sclerosis, Relapsing-Remitting

Summary: studying the effectiveness of a functional rehabilitation protocol (frp) in early relapsing remitting multiple sclerosis (rrms) patients treated with betaferon by comparing the physical ability of patients with and without frp.


Eligibility criteria:
inclusion criteria: * female and male patients aged 18 and more; * confirmed diagnosis of rrms according to the macdonald or poser criteria; * first indication for betaferon treatment (as described in summary of product characteristics (smpc)); * no relapse of multiple sclerosis (ms) in the last two months before the inclusion; * walking patients having an expanded disability status scale (edss) score between \> 1 and \</= 4 at the inclusion visit; * female of child-bearing potential must agree to practice adequate contraception methods over all the duration of the study; * patient can follow all the study and comply with all procedures of the trial protocol * laboratory evaluations (i.e. evaluation of hepatic enzymes gammagt, full blood count and differential white blood cell \[wbc\]) must be available and the results must be normal; * written informed consent. exclusion criteria: * any contraindication to betaferon as described in the smpc of the product; * patient with a previously orthopaedic surgical intervention within the past year of the inclusion; * patient previously included in this study; * patient previously treated within the past 3 months with rebif, avonex or copaxone; * patient previously treated within the past 12 months with betaferon; * participation in any clinical trial within the past 30 days involving the investigational drug intake.

Keywords: kinesep rehabilitation betaferon
ai-assisted facial surgical planning

Conditions: Facial Plastic and Reconstructive Surgery; Periocular Diseases; Orbital Diseases; Artificial Intelligence

Summary: computer vision using deep learning architecture is broadly used in auto-recognition. in the research, the deep learning model which is trained by categorized single-eye images is applied to achieve the good performance of the model in blepharoptosis auto-diagnosis.

this auto-diagnosis system of blepharoptosis using machine learning architecture will assist in telemedicine, such as early screening of childhood ptosis for prompt referral and treatment. people could use this software via mobile devices to get a primitive diagnosis before they reach the physicians. furthermore, in primary health care, where there is no oculoplastic surgeon, the software could assist primary care physicians or general ophthalmologists, in identifying the need for a referral.

Eligibility criteria:
\[inclusion criteria\] 1. the participants who were 20-year-old or above, 2. surgical informed consent was endorsed by the participants themselves, 3. participants who have surgical indications of the oculofacial surgeries, and 4. the participants who agreed on photograph taking after explanation by the surgeon at outpatient clinics. \[exclusion criteria\] 1. the participants who were 19-year-old or under, 2. the participants who don't have surgical indications of the oculofacial surgeries, 3. the participants who were designed for minimal invasive treatments, such as botox or any kind of fillers injection, 4. the participants who refused photograph taking for any reason, and 5. the participants who are not available for standard quality of photograph taking, such as bedridden patients.

Keywords: facial plastic and reconstructive surgery periocular diseases orbital diseases artificial intelligence
evaluation of 2 doses of intravenous droperidol in the prevention of postoperative nausea

Conditions: Nausea; Vomiting

Summary: in this prospective, randomised, placebo-controlled study, the researchers determined whether 0.625 mg or 2.5 mg of iv droperidol given 30 min before emergence from general anaesthesia reduces the incidence of immediate and delayed post operative nausea and vomiting (ponv) in thyroid surgical female population. two hundred and forty six female patients receiving general anaesthesia for thyroid surgery received either droperidol 0.625 mg or droperidol 2.5 mg or placebo before emergence.

* principal objective : our study examined one main question: are there difference in efficacy between droperidol iv 0.625 mg or 2.5 mg for the treatment or prophylaxis of ponv to surgical patient undergoing thyroid surgery when they receive it 30 min before emergence from general anaesthesia? * secondary objective : * comparison of the % of patients in every group: * having a complete control of their nausea * requiring secondarily the appeal to another anti-emetic treatment in postoperative * presenting an adverse event * compare score of sedation in ach groups * evaluate electrocardiograph * compare the morphine consumption * study design : prospective, randomized, monocenter, double-blind study * inclusion criteria : * female * more than 18 years old * patients scheduled for thyroid surgery * simplified apfel score ≥ 2 * asa score : 1-2 * informed consent obtained from the patient * the women in age of procreate must have a reliable contraceptive method * exclusion criteria : * age \< 18 years old * male * obesity * present a severe depressive syndrome * pregnancy women * trouble of cardiac rate * alcoholism * contra-indication for droperidol prescription * study plan: three parallel groups will receive 2 different doses of droperidol or placebo at the end of surgery. * group 1: 0,625mg of droperidol at the end of surgery * group 2: 2,5mg of droperidol at the end of surgery * group 3: placebo at the end of surgery * number of subjects : 246

Eligibility criteria:
inclusion criteria: * female * more than 18 years old * patients scheduled for thyroid surgery * simplified apfel score ≥ 2 * asa score : 1-2 * informed consent obtained from the patient * women able to procreate must have a reliable contraceptive method exclusion criteria: * age \< 18 years old * male * obesity * has a severe depressive syndrome * pregnancy women * trouble with cardiac rate * alcoholism * contra-indication for droperidol prescription

Keywords: thyroidectomy nausea vomiting droperidol